Comparison of in vitro activities of antifungal drugs and ethanolic extract of propolis against Trichophyton rubrum and T. mentagrophytes by using a microdilution assay

Mycoses

Volumn 48, Issue 3, 2005, Pages 205-210

  Koc, A N ^a   Silici, Sibel ^a   Ayangil, D ^a   Ferahbas A ^a   Cankaya S ^b  

^a ERCIYES UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Antifungal activity; Antifungal agents; Dermatophytes; Microdilution method; Propolis

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PROPOLIS; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DERMATOMYCOSIS; DERMATOPHYTE; DILUTION; DRUG POTENCY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM;

ANTIFUNGAL AGENTS; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; PROPOLIS; TRICHOPHYTON; TURKEY;

EID: 17844401495     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2005.01128.x     Document Type: Article

References (39)

1. Larone DH. Culture and identification of dermatophytes. Clin Microbiol Newsl 1996; 18: 33-8.
2. Elewski EB. Onychomycosis: pathogenesis, diagnosis and management. Clin Microbiol Rev 1998; 11: 415-29.
3. Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol 2000; 39: 385-8.
4. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992; 14: 161-9.
5. Roberts DT, Cox NH, Gentles JC, Babu KKR. Comparison of ketoconazole and griseofulvin in the treatment of tinea pedis. J Vet Med Mycol 1994; 25: 347-50.
6. Grupta AK, Sauder DN, Shear NH. Antifungal agents: an overview (Part II). J Am Acad Dermatol 1994; 30: 911-33.
7. Clayton YM. In vitro activity of terbinafine. Clin Exp Dermatol 1989; 14: 101-3.
8. Jessup CJ, Warner J, Isham N, Hasan I, Ghannoum MA. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341-4.
9. Bankova V, Marcucci MC. Standardization of propolis: present status and perspectives. Bee World 2000; 81: 182-8.
10. Kujumgiev A, Bankova V, Ignatova A, Popov S. Antibacterial activity of propolis, some of its components and their analogs. Pharmazie 1993; 48: 785-6.
11. Moreno MIN. Isla MI, Cudmani NG, Vattuone MA, Sampietro AR. Screening of antibacterial activity of Amaiche del Valle (Tucuman, Argentina) propolis. J Ethnopharmacol 1999; 68: 97-102.
12. Sforcin JM, Fernendes A Jr, Lopes CAM, Funan SRC, Bankova V. Seasonal effect of Brazilian propolis on Candida albicans and Candida tropicalis. J Venom Anim Toxins 2001; 7: 139-44.
13. Ota C, Unterkircher C, Fantinato V, Shimizu MT. Antifungal activity of propolis on different species of Candida. Mycoses 2001; 44: 375-8.
14. Sawaya ACHF, Palma AM, Caetano FM et al. Comparative study of in vitro methods used to analyze the activity of propolis extracts with different compositions against species of Candida. Lett Appl Microbiol 2002; 35: 203-7.
15. Kartal MS, Kaya S, Kurucu S. GC-MS analysis of propolis samples from two different regions of Turkey. Z Naturforsch 2002; 57c: 905-9.
16. Cafarchia C, De Laurenthis N, Milillo MA, Losacco V, Puccini V. Antifungal activity of Apulia region propolis. Parassitologia 1999; 41: 587-90.
17. D'Auria FD, Tecca M, Scazzocchio F, Renzini V, Strippoli V. Effect of propolis on virulence factors of Candida albicans. J Chemother 2003; 15: 454-60.
18. Larone DH. Medically Important Fungi: a Guide to Identification, 2nd edn. Washington, DC, USA: American Society for Microbiology Press, 1993: 117-37.
19. Kane J, Summerbell RC. Trichophyton, Microsporum, Epidermophyton, and agents of superficial mycoses. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds). Manual of Clinical Microbiology, 7th edn. Washington, DC, USA: American Society for Microbiology Press, 1999: 1275-94.
20. Tümbay E. Pratik Tip Mikolojisi, Bilgehan Basimevi. İzmir: 1984: 69.
21. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-forming Filamentous Fungi: Proposed Standard. NCCLS document M38-P. Wayne, PA, USA: NCCLS, 1998.
22. Espinel-Ingroff A, Barlett M, Bowden R et al. Multicenter of evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997; 35: 139-43.
23. Espinel-Ingroff A, White T, Pfaller MA. Antifungal agents and susceptibility tests. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds). Manual of Clinical Microbiology, 7th edn. Washington, DC, USA: ASM Press. 1999: 1640-52.
24. Ghannoum MA. Antifungal susceptibility testing of dermatophytes. Dermatol Online J 2001; J7: 23C.
25. Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of in vitro activity of terbinafine. Med Mycol 2000; 38: 155-9.
26. Espinel-Ingroff A, Kish CW, Kerkering TM et al. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 1992; 30: 3138-45.
27. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996; 34: 489-95.
28. Korting HC, Ollert M, Abeck D and the German Collaborative Dermatophyte Drug Susceptibility Study Group. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing Tinea unguium. Antimicrob Agents Chemother 1995; 39: 1206-8.
29. Fernandez-Torres B, Vazquez-Veiga H, Llova X, Pereiro M, Guarro J. In vitro susceptibility to itraconazole, clotrimazole, ketoconazole, and terbinafine of 100 isolates of Trichophyton rubrum. Chemotherapy 2000; 46: 390-4.
30. Fernandez-Torres B, Carrillo AJ, Martin E et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother 2001; 45: 2524-8.
31. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-44.
32. Balfour JA, Foulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial mycoses. Drugs 1992; 43, 259-84.
33. Millet-Clerc J, Miclhel D, Simeray J, Chaumont JP. Etude preliminaire des proprietes fongistatiques de la propolis compares a celles de queques produits commerciaux. Plant Med Phytother 1987; 21: 3-7.
34. Soares MMSS, Cury AE. In vitro activity of antifungal and antiseptic agents dermatophyte isolates from patients with tinea pedis. Braz J Microbiol 2001; 32: 130-4.
35. Lindenfelser AL. Antimicrobial activity of propolis. Am Bee J 1967; 107: 90-2.
36. Ghisalberti E. Propolis: a rewiev. Bee World 1979; 60: 59-84.
37. Bankova VS, Castro SL, Marcucci MC. Propolis: recent advances in chemistry and plant origin. Apidologie 2000; 31: 3-15.
38. Velikova M, Bankova V, Sorkun K, Houcine S, Tsvetkova I, Kujumgiev A. Propolis from Mediterranean Region: chemical composition and antimicrobial activity. Z Naturforsch 2000; 55c: 790-3.
39. Popova M, Silici S, Kaftanoǧlu O, Bankova V. Antibacterial activity of Turkish propolis and its qualitative and quantitative chemical composition. Phytomedicine 2005; 12: 221-228.